Newsfile Corp
07 Jul 2026, 20:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
GeneDx cut its 2026 revenue guidance from $540-555 million to $475-490 million. — Significant downward revisions to revenue guidance typically trigger immediate negative sentiment and a devaluation of the stock.
-0.80GeneDx took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition just one year after purchasing it for $36.5 million. — An impairment of nearly 85% of an acquisition's value suggests a major failure in strategic execution or overpayment, impacting the balance sheet.
-0.70The company's average reimbursement rates came in at $3,300, which was $200 below market expectations. — Lower-than-expected reimbursement rates directly compress margins and indicate a weakening of the core business model's profitability.
-0.50Continue reading
6 related stories
Top 3 movers · tap to explore
A federal securities class action lawsuit has been filed alleging that GeneDx executives made false or misleading statements regarding business prospects and margins. — Class action lawsuits create legal overhang and potential financial liabilities, though they are common following sharp price drops.
-0.40Which stocks this story touches
The company is facing a federal securities class action lawsuit following a 49% stock price drop, missed financial results, and guidance cuts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
